RxSight, Inc.: Piper Sandler cuts target price to $8 from $10
RXST•Piper Sandler cut its target price for RxSight, Inc. to $8 from $10.
Related News
BioMarin Pharmaceutical Inc.: JP Morgan cuts target price to $86 from $87
BMRN•
Xometry raises target price to $117 from $100
XMTR•
Leerink Partners cuts Ideaya Biosciences target price to $30 from $31
IDYA•
Incyte target price cut to $150 from $154 by Leerink Partners
INCY•
Needham cuts Dynatrace target price to $65 from $68
DT•